Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens
US12109261B1 · kind B1 · utility
0Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2024 |
| Grant date | Oct 8, 2024 |
| Priority date | — |
| Expiry date | May 22, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16334
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel engineered influenza hemagglutinin (HA) proteins, related polynucleotide sequences, and vaccine compositions including nanoparticle compositions. Relative to a wildtype HA protein, the engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating influenza viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.